<DOC>
	<DOCNO>NCT00193219</DOCNO>
	<brief_summary>This trial evaluate combination modify infusional 5-fluorouracil/ leucovorin , oxaliplatin ( FOLFOX6 ) , bevacizumab , cetuximab patient metastatic colorectal cancer . FOLFOX6 proven safe effective regimen first line treatment advance colorectal cancer . The role epidermal growth factor ( EGFR ) inhibitor earlier treatment set combination optimal chemotherapy regimens important emerge question .</brief_summary>
	<brief_title>Bevacizumab Cetuximab Combination With FOLFOX6 Patients With Metastatic Colorectal Cancer</brief_title>
	<detailed_description>All patient receive cetuximab : 400 mg/m2 ( first cycle ) administer intravenously ( IV ) day 1 250 mg/m2 IV day 8 subsequent cycle 250 mg/m2 IV day 1 8 . Day 1 cetuximab immediately follow bevacizumab 5 mg/kg IV , oxaliplatin 85 mg/m2 IV , 5-fluorouracil 400 mg/m2 IV bolus , follow 2400 mg/m2 administer continuous infusion 46 hour via pump ( outpatient ) leucovorin 350 mg IV ( modify FOLFOX6 ) . Cycles 14 day .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Colonic Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>To include study , must meet following criterion : Metastatic colorectal cancer confirm biopsy sample 18 year age old Evidence disease progression time study entry At least one prior adjuvant chemotherapy regimen No prior therapy metastatic disease Measurable disease Able perform activity daily live minimal assistance Adequate bone marrow , kidney , liver function Tumor tissue available assessment EGFR Signed informed consent You participate study follow apply : Treatment previous regimen metastatic disease Prior treatment EGFR inhibitor antiangiogenic agent Brain nervous system metastases History severe thromboembolic event Clinical evidence history bleed coagulopathy History stroke heart attack within six month Poorly control hypertension Nonhealing wound , ulcer , bone fracture History abdominal fistula , perforation , abscess within six month Other uncontrolled significant disease medical condition Please note : There additional inclusion/exclusion criterion . The study center determine meet criterion . If qualify trial , study personnel explain reason . If qualify , study personnel explain trial detail answer question may . You decide wish participate .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>Colon Cancer</keyword>
</DOC>